Yuflyma (adalimumab-aaty), and its unbranded version, are now approved for two additional pediatric indications – adolescent ...

ORLANDO -- Adalimumab (Humira) was more effective than conventional immunosuppressive drugs at lowering or eliminating the ...

US FDA approves expanded paediatric indications for Celltrion’s Yuflyma and unbranded adalimumab-aaty: Incheon, South Korea Monday, October 20, 2025, 17:00 Hrs [IST] Celltrion, ...

YUFLYMA® (adalimumab-aaty), and its unbranded version, are now approved for two additional pediatric indications - adolescent hidradenitis suppurativa (HS) and ...

In a first, Colorado will cap the price of Enbrel, an arthritis drug. Using patent tactics, the drugmaker Amgen has ...

At 24/7 Wall St., we have closely followed dividend-paying stocks for over 15 years. With a growing audience of savvy Baby ...

Stocks rose to begin a busy week that will see a flurry of corporate earnings reports, with investors also awaiting further ...

Key Takeaways Economists say the flurry of policies aimed at forcing drug companies to lower prices may not be as effective ...

Patients with noninfectious intermediate, posterior, or panuveitis requiring immunosuppressive therapy are less likely to ...

Oct 20 (Reuters) - Global drugmakers are rushing to boost U.S. manufacturing and inventory as the Trump administration weighs a 100% tariff on imported branded and patented drugs. Although enforcement ...